Pharmatest is excited to join the meeting onsite from April 8 through 13, 2022 at the Ernest N. Morial Convention Center in New Orleans.
The AACR Annual Meeting is the focal point of the cancer research, where community gather to share the latest advances in cancer science and medicine. The AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
If you are attending AACR in-person, stop by and visit our team at booth #1465. To schedule a personal meeting, send us a message to info@pharmatest.com.
Launching new oncology services
Pharmatest is continuously pursuing improvements in our services and during AACR we will be launching two new models for oncology research. These new models, Syngeneic model of HM-1 ovarian cancer and Orthotopic model of hepatocellular carcinoma (poster #1662), complement nicely Pharmatest’s current portfolio of oncology services.
Presenting new data
We are joining AACR with four poster our posters in collaboration with Bayer AG, Bayer AS and Aurexel Life Sciences Ltd. Be sure to check out posters onsite or virtually!
Poster #1624/16
Title: Orthotopic model of Hepatocellular Carcinoma (HCC) using Huh-7 and HepG2 cells, application of micro-CT in detection of cancer progression.
April 11, 2022, 1:30 PM – 5:00 PM, Section 11
Poster #1662/24
Title: Orthotopic model of Hepatocellular Carcinoma (HCC) using Huh-7 and HepG2 cells, application of micro-CT in detection of cancer progression.
April 11, 2022, 1:30 PM – 5:00 PM, Section 12
Co-author with Bayer AS
Poster #3311/9
Title: Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model.
April 12, 2022, 1:30 PM – 5:00 PM, Section 25
Co-author with Bayer AG
Poster #3318/16
Title: PSMA-targeted thorium-227 conjugate (PSMA-TTC) inhibits tumor growth and abnormal bone changes in the intratibial LNCaP xenograft model of bone-metastatic prostate cancer.
April 12, 2022, 1:30 PM – 5:00 PM, Section 25
Co-author with Bayer AG and Aurexel Life Sciences Ltd
